Clinical trials: High-dose Interleukin-2
Leukemia, Lymphoma
Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 following bone marrow transplantation in treating patients who have…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003962
- Testing
- aldesleukin
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Candidiasis, Oral, Gastrointestinal Diseases
A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2
In patients who are receiving intravenous high dose Interleukin-2, patients will be randomized into two groups: group one will receive nystatin swish and swallow immediately before initiation of IL-2, and the second group will…
- Conditions
- Candidiasis, Oral, Gastrointestinal Diseases, Stomatitis
- Trial name
- NCT00001812
- Testing
- Nystatin
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow or peripheral stem cell transplantation may allow the doctor to give…
- Trial name
- NCT00014573
- Testing
- aldesleukin, autologous tumor cell vaccine, filgrastim
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
HIV Infections
Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems
The purpose of this study is to determine the safety of a drug called interleukin-2 (IL-2) given with anti-HIV therapy in children with HIV infection. This study will also determine the best dose of IL-2 to give children.
- Trial name
- NCT00006066
- Testing
- Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Diphtheria and Tetanus Toxoids Adsorbed, Tetanus and Diphtheria Toxoids Adsorbed
- Where
- 14 sites in United States, Puerto Rico
- Volunteers
- 92 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Metastatic Renal Cell Carcinoma, Metastatic Melanoma
Interleukin-2-Induced Cognitive/Affective/Sleep Symptoms
-Purpose: Phase I: To test the methods, data collection and analysis in a study to evaluate cognitive/affective/sleep symptoms in one patient undergoing treatment with high-dose Interleukin-2 (IL-2) for metastatic renal cell…
- Conditions
- Metastatic Renal Cell Carcinoma, Metastatic Melanoma, High-dose Interleukin-2
- Trial name
- NCT02150369
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Duke University
Leukemia
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Trial name
- NCT00008190
- Testing
- aldesleukin, filgrastim, busulfan
- Where
- United States
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Breast Cancer
Biological Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Peripheral stem cell transplantation combined with biological therapy may be an effective treatment for breast…
- Trial name
- NCT00002616
- Testing
- aldesleukin, filgrastim, carboplatin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Illinois Chicago
Kidney Cancer
Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer
The purpose of this study is to assess the efficacy of post-operative high-dose bolus interleukin-2 (IL-2) in patients with high-risk renal cell carcinoma (RCC).
- Trial name
- NCT00003126
- Testing
- Interleukin-2
- Where
- 15 sites in United States
- Volunteers
- 69 people
- Sponsor
- Loyola University
Leukemia
Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
RATIONALE: Giving combination chemotherapy before a peripheral blood stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them.
- Trial name
- NCT00004128
- Testing
- aldesleukin, filgrastim, busulfan
- Volunteers
- 2,000 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7
Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma
This pilot phase I trial studies the side effects and best dose of genetically modified T-cells followed by aldesleukin in treating patients with stage III-IV melanoma.
- Conditions
- Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7
- Trial name
- NCT01955460
- Testing
- Aldesleukin, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma (Skin)
Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines may make the body build an immune response that will kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells.
- Trial name
- NCT00003568
- Testing
- aldesleukin, gp100 antigen, incomplete Freund's adjuvant
- Where
- 9 sites in United States
- Sponsor
- University of Illinois Chicago
Neuroblastoma
A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells
The investigators intend to test the safety, and immunologic and clinical efficacy of a combination of 2 allogeneic neuroblastoma tumor cell line vaccines, one of which has been genetically modified to secrete the…
- Trial name
- CHESAT (NCT00703222)
- Testing
- SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 1 SKNLP, SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 2 SKNLP
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Baylor College of Medicine
Lymphoma
Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with autologous stem cell transplantation may allow the doctor to give higher doses…
- Trial name
- NCT00070187
- Testing
- aldesleukin, filgrastim, recombinant interferon gamma
- Where
- 63 sites in United States, Australia and 1 more
- Volunteers
- 24 people
- Sponsor
- Children's Oncology Group